image: ISN logo view more
Credit: ISN
Rio de Janeiro, Brazil, April 22, 2007 – The International Society of Nephrology (ISN) today announced Eduardo Slatopolsky, Joseph Friedman Professor of Renal Diseases in Medicine, Washington University School of Medicine (St. Louis, Missouri - USA) as the 2007 winner of the ISN Amgen International Prize for Therapeutic Advancement in Nephrology.
Established in 2003, the ISN Amgen International Prize recognizes those who have increased the understanding and treatment of kidney disease through basic or clinical scientific research, leading to therapeutic advances. This year's prize specifically recognizes Slatopolsky's pioneering experimental research in mineral metabolism which has undoubtedly improved the lives of patients with renal failure around the world.
With over 400 publications in basic and clinical sciences related to mineral metabolism – a testament to his outstanding contribution to the field, Slatopolsky has dedicated his entire career to the study of kidney disease with a 30 year record of major scientific achievements.
Receiving the prestigious prize during the 2007 Donald Seldin Plenary Lecture at the World Congress of Nephrology on April 22, Eduardo Slatopolsky expressed his thanks to ISN, Amgen and recognized the contribution of his laboratory members,
"I am deeply moved to be the recipient of this award of the ISN… it is a unique privilege that I have been selected for the ISN Amgen International Prize for Therapeutic Advancement in Nephrology. I accepted on behalf of my colleagues, with tremendous gratitude for having been selected as recipient."'
"Amgen congratulates Eduardo Slatopolsky on this important recognition by the ISN," said Robert Brenner, M.D. Executive Director Nephrology Medical Affairs. "Dr. Slatopolsky has made broad contributions to our understanding of the pathophysiology of secondary hyperparathyroidism, hyperphosphatemia and vitamin D biology. His efforts have driven treatment advances for patients with kidney disease around the world."
For media-related enquiries, please contact: Amanda Wren, International Society of Nephrology, Email: amanda.wren@isn-online.org, GSM: +32-473938672
EDITOR'S NOTES
1) The International Society of Nephrology is a not-for-profit society whose mission is the global advancement of nephrology. The Society promotes research and education to prevent and treat kidney disease throughout the world. Further information is available at: http://www.isn-online.org/, or by contacting the ISN's Global Headquarters: +32-2-743 1546, Email: info@isn-online.org.
2) Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.